BioNTech Resultados de beneficios anteriores

Pasado controles de criterios 2/6

BioNTech ha aumentado sus beneficios a una tasa media anual de 44.7%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.7% anual. Los ingresos han ido creciendo a una tasa media de 45.2% al año. La rentabilidad financiera de BioNTech es de 4.6%, y sus márgenes netos son de 24.4%.

Información clave

44.7%

Tasa de crecimiento de los beneficios

44.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	45.2%
Rentabilidad financiera	4.6%
Margen neto	24.4%
Próxima actualización de resultados	06 May 2024

Actualizaciones de resultados anteriores recientes

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

Recent updates

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

BioNTech: A Tale Of 2 Companies

Sep 20

European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot

Sep 12

CDC advisors to vote on COVID Omicron vaccines on Sept. 1

Aug 30

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero BioNTech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:BNTX Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	3,819	930	558	1,783
30 Sep 23	6,618	2,751	569	1,715
30 Jun 23	9,184	4,375	564	1,559
31 Mar 23	12,213	6,238	571	1,585
31 Dec 22	17,311	9,434	541	1,537
30 Sep 22	18,565	10,322	556	1,299
30 Jun 22	21,191	11,748	480	1,217
31 Mar 22	23,303	12,863	394	1,019
31 Dec 21	18,977	10,293	327	949
30 Sep 21	13,790	7,493	229	935
30 Jun 21	7,770	4,072	178	902
31 Mar 21	2,503	1,197	139	796
31 Dec 20	482	15	109	645
30 Sep 20	165	-410	79	453
30 Jun 20	126	-230	63	275
31 Mar 20	110	-192	57	232
31 Dec 19	109	-179	49	227
30 Sep 19	144	-122	53	208
30 Jun 19	136	-116	48	191
31 Mar 19	132	-77	38	168
31 Dec 18	128	-48	32	141
31 Dec 17	62	-86	34	82

Ingresos de calidad: BNTX tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(24.4%) de BNTX son inferiores a los del año pasado (54.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BNTX ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 44.7% al año.

Acelerando crecimiento: BNTX ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: BNTX tuvo un crecimiento negativo de los beneficios (-90.1%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-8.9%).

BioNTech Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Recent updates

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

Independent Supervisory Board Chairman notifies of intention to sell stock

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Consensus EPS estimates fall by 15%

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 10%

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Investor sentiment deteriorated over the past week

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Investor sentiment deteriorated over the past week

Desglose de ingresos y gastos
Beta